The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.

The present invention is directed to PVRIG polypeptides and their uses.

The present invention relates to a method for preparing a whole bovine-derived broadly neutralizing antibody against serotype O foot-and-mouth disease virus, and belongs to the technical field of antibody preparation. The preparation method of the present invention includes the following steps: 1) conducting the first, second and third immunization on the cattle by using the serotype O foot-and-mouth disease virus; 2) screening for the serotype O foot-and-mouth disease virus antigen-specific single B cells; 3) amplifying variable region genes of the heavy and light chains of the bovine antibody; 4) acquiring constant region sequences of the heavy and light chains of the bovine antibody; 5) preparing a full-length heavy chain vector of the whole bovine-derived monoclonal antibody and a full-length light chain vector of the whole bovine-derived monoclonal antibody; 6) co-transfecting a cell with the full-length heavy chain vector of the whole bovine-derived monoclonal antibody and the full-length light chain vector of the whole bovine-derived monoclonal antibody, taking the supernatant of cell culture, and purifying to obtain the whole bovine-derived broadly neutralizing antibody against the serotype O Foot-and-mouth disease virus. The preparation method of the present invention utilizes different foot-and-mouth disease virus strains to infect cattle and obtains a neutralizing antibody capable of neutralizing three topotypes of serotype O FMDVs by screening, and thus can obtain a whole bovine-derived broadly neutralizing monoclonal antibody.

The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.

A virus-like particle of Senecavirus A, the particle including a structural protein VP0, a structural protein VP1 and a structural protein VP3. The structural protein VP0 is encoded by a gene sequence represented by SEQ ID NO: 1. The structural protein VP1 is encoded by a gene sequence represented by SEQ ID NO: 2. The structural protein VP3 is encoded by a gene sequence represented by SEQ ID NO: 3.

The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.

The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.

The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).

A virus-like particle of Senecavirus A, the particle including a structural protein VP0, a structural protein VP1 and a structural protein VP3. The structural protein VP0 is encoded by a gene sequence represented by SEQ ID NO: 1. The structural protein VP1 is encoded by a gene sequence represented by SEQ ID NO: 2. The structural protein VP3 is encoded by a gene sequence represented by SEQ ID NO: 3.

A peptide comprising the rhinovirus immunogen peptide of the rhinovirus structural protein 1 (VP1) of rhinovirus C and related vaccines and therapeutic compositions is disclosed.